|Bid||23.21 x 1000|
|Ask||23.35 x 1300|
|Day's Range||22.37 - 23.67|
|52 Week Range||16.05 - 37.72|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||65.22|
|Earnings Date||Oct 1, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||27.00|
Bill Gurley, a general partner of Benchmark Capital, bought $3.1 million of the online-clothing retailer’s shares. It’s the first time a Stitch Fix insider has bought stock on the open market since the company’s IPO in November 2017.
Those following along with Stitch Fix, Inc. (NASDAQ:SFIX) will no doubt be intrigued by the recent purchase of shares...
A recession could be headed your way, warns Goldman Sachs -- and that's okay.In a recent report, Goldman private wealth management chief investment officer Sharmin Mossavar-Rahmani put the chances of a recession hitting the U.S. in 2020 at somewhere between 25% and 30% -- triple the risk seen three years ago. Despite the risk, though, there's also still opportunity to profit from owning the right companies.Jobs numbers in the U.S. remain strong. GDP growth is expected to end this year at 2.3%, then slow in 2020, but still remain above 2% -- not negative at all. And in the event a recession does not occur, 86% of the time, says Mossavar-Rahmani, stocks continue to go up!So which stocks does Goldman Sachs recommend that you buy "just in case?"Utilizing the Stock Screener at TipRanks, We've found three stocks receiving "buy" ratings from most analysts in general, and endorsed by Goldman Sachs in particular. Let's take a closer look:Stitch Fix (SFIX)Stitch Fix is a clothing by mail subscription service, mailing its customers monthly deliveries of clothes, shoes, and accessories, which customers can then peruse and either accept (and pay for) or mail back (and not). But while the business model may bear a whiff of "Columbia House CDs," it's doing a whole lot better than its predecessor in concept.With profit margins intact, guiding for 11% to 13% EBITDA margins, 5-star Goldman Sachs analyst Heath Terry sees SFIX stock as attractively priced "below the ecommerce sector average despite faster revenue and EBITDA growth." Terry rates Stitch Fix a 'buy' with a $24 price target -- implying 20% upside from today's prices. (To watch Terry's track record, click here)Terry points out, Stitch Fix nailed analyst estimates with sales of $432 million. Adjusted for a slightly longer quarter than Q4 2018 had in it, the analyst says grew 26% year over year, and management's "FY20 revenue guidance of +20.5% -22.5% ... bracketed consensus" expectations as well.Client rolls are expanding at a "stable" rate, "spend per client" is also growing nicely, and the company is expanding its business both internationally (to the UK) and categorically, as Stitch Fix promotes subscriptions for children's clothing.When looking at Wall Street’s stance, Terry is not the only bull, as TipRanks analytics showcase SFIX as a Buy. Out of 9 analysts polled in the last 3 months, 5 rate SFIX a 'buy', while 4 say 'hold'. The 12-month average price target stands at $26.89 marking an 37% upside from where the stock is currently trading. (See SFIX's price targets and analyst ratings on TipRanks)Wynn Resorts (WYNN)Not interested in "gambling" on whether consumers will take a fancy to clothing subscriptions? Perhaps a more straightforward gambling play is more to your taste? Here, Goldman analyst Stephen Grambling offers up Wynn Resorts, the Las Vegas-based casino operator that now gets 75% of its revenues from the island of Macau in... China!At present, more than half of Wynn's physical assets still call the United States home, and the company is investing heavily in "major capital projects" in Boston and Las Vegas, which have been a drain on cash. But as Grambling points out, free cash flow at Wynn "is set to inflect" as these projects come to completion, even as the company's Macau properties have "potential for upside," helping to pull Wynn stock up from a "near-trough valuation" to as high as $155 a share. (To watch Grambling's track record, click here)Indeed, of all the casino operators that Goldman Sachs covers, Grambling believes Wynn has the best potential for upside -- as much as 46%, versus 33% for Las Vegas Sands for example. With a 14-ish P/E ratio and a 14%-ish projected earnings growth rate on the Street -- and a strong 3.6% dividend yield to boot -- the analyst believes Wynn is poised to outperform.Overall, Wall Street sizes up Wynn Resorts as a ‘Moderate Buy’ stock, as the bulls edge out the cautious on the Las Vegas gaming and hospitality giant. In the last 3 months, WYNN has received 7 bullish ratings versus 3 analysts hedging their bets. The 12-month average price target of $135.20 reflects a potential upside of 24%. (See WYNN's price targets and analyst ratings on TipRanks)Seattle Genetics (SGEN)Switching gears (rather dramatically I should say) from consumer-focused stocks to the bright, shiny new world of biotech, Goldman Sachs' third buy-rated pick today is Seattle Genetics, a rising force in the world of oncology.Goldman Sachs analyst Salveen Richter rates SGEN a "buy" with a $100 price target (the stock costs $84 today) on hopes that increased use of Advetris to treat Hodgkin's lymphoma and peripheral T cell lymphoma will prove to be "pipeline drivers to cement SGEN's transition into a multi-product oncology company." (To watch Richter's track record, click here)Richter further expects new drugs enfortumab vedotin to receive FDA approval as early as March 2020, and is "positive" on the prospects for two more drugs in late-stage clinical trials, "tucatinib" for treating metastatic breast cancer and tisotumab vedotin for use against metastatic cervical cancer. Those clinical results are due out before the end of this year, and in the first half of next year, respectively. And Seattle Genetics has a nice pipeline of similarly tongue-twisting drug candidates waiting in line behind those.In terms of dollars and cents, of course, there's little here to attract value investors. At least, Richter doesn't see any potential for GAAP profits through at least 2021. (On the other hand, the consensus on Wall Street is that S-Gen will in fact earn a profit in 2021). Whichever way things play out on the profit front, revenue growth alone may be enough to support Seattle Genetics stock, with Richter projecting a rough doubling in sales to $1.29 billion by 2021.That's good enough for a "buy" rating in Goldman Sachs' estimation -- and a 19% profit for investors buying at today's prices.The initial word out on the Street echoes Richter's bullish conviction on the drug maker, as TipRanks analytics showcase SGEN as a Buy. Based on 15 analysts polled in the last 3 months, 10 are bullish on the stock, while 4 remain sidelined and one (Merrill Lynch) is bearish. (See SGEN's price targets and analyst ratings on TipRanks)
Although Stitch Fix Inc’s (NASDAQ: SFIX ) new Direct Buy initiative is still in its nascent stages, it would allow consumers to engage beyond the traditional format and drive incremental sales, according ...
Stitch Fix's (SFIX) bottom line beat the consensus mark while revenues came in-line. Also, FY20 and first-quarter view remains a concern. However, both the top and bottom lines grew year-over-year.
Stitch Fix Inc. stock plummets after revenue that misses expectations; however, analysts are bullish that a new direct purchase program for consumers, Shop Your Looks, will keep Amazon.com Inc. at bay.
Stitch Fix stock dove Wednesday as the online provider of personalized apparel reported quarterly results that met expectations but delivered an outlook that missed Wall Street estimates.
This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform. TD Ameritrade (NASDAQ: AMTD ) shares were ...
Stitch Fix Inc (NASDAQ: SFIX ) shares were plummeting Wednesday after the online styling service delivered a fourth-quarter sales miss. KeyBanc A Long-Term Believer Investments in data scientists and ...
Shares of the online personal stylist are down more than 50% from their all-time high, with a price/revenue multiple in the one-times range. But analysts are concerned about growth and earnings.
Stitch Fix shares moved sharply lower despite better-than-feared fourth quarter results after management's guidance came in below expectations.
Tuesday, I discussed "bottoming" versus "a bottom." Stitch Fix has all the characteristics of a bottom in play. Despite the weak action, we are seeing a higher low in the StochRSI (bullish divergence) and another potential bullish divergence with the Full Stochastics. While we don't have a ton of post-earnings history to go off of in terms of negative action on the day after the report, we can examine the four times it has happened since Stitch Fix came public.
Stocks finish down sharply again on Wednesday on a slump in U.S. manufacturing, recession fears, and a disappointing hiring report.
Happy hump day! Do you hear the people singing? Jim Cramer breaks down whether or not those recession bells are real or if you're just listening to too much Les Mis and Starbucks and Real Money Stock of the Day Stitch Fix . Cramer wrote about Starbucks in his Real Money column on Wednesday morning.
Stitch Fix Inc. reported its fiscal fourth-quarter results Tuesday evening. The online clothing retailer beat fiscal fourth-quarter earnings expectations but issued a weaker-than-expected revenue forecast for the first quarter.
Shares fall after the online clothing retailer beats fiscal fourth-quarter earnings expectations but issues a weaker-than-expected revenue forecast for the first quarter.
U.S. stock futures point lower following the biggest single-day decline on Wall Street in more than a month after a grim reading of U.S. factory activity; Johnson & Johnson settles opioid lawsuits with two Northeast Ohio counties for $20.4 million; Visa, Mastercard and other financial partners that agreed to help build and maintain Facebook's Libra cryptocurrency-based payments network are reconsidering their involvement, a report says.